Gene · 90
ACVR1: activin A receptor type 1
12 sourcesgene-search-2026-11-11-0.2.0
Cite this record
ConductScience Library. ACVR1: activin A receptor type 1. Genes, record 90. Release gene-search-2026-11-11-0.2.0, 11 Nov 2026. https://conductscience.org/library/genes/90
On this page
Gene
Proteins1
Reviewed human proteins whose Swiss-Prot entry states the gene.
| UniProt entry | Protein | Length | Structures | Gene stated in |
|---|---|---|---|---|
| Q04771 | Activin receptor type-1 | 509 | 85 | Ensembl, GeneID, HGNC |
Source UniProt
Patents173
Patents whose sequence listing contains this protein's exact sequence. A patent can list a sequence without claiming it.
| Publication | Published | SEQ ID NO | Protein | Source |
|---|---|---|---|---|
| JP 2026514618 A | 2026-05-13 | 61 | Q04771 | Espacenet |
| EP 4698654 A1 | 2026-02-25 | 25 | Q04771 | Espacenet |
| JP 2026004568 A | 2026-01-14 | 36225 | Q04771 | Espacenet |
| JP 2026004568 A | 2026-01-14 | 36226 | Q04771 | Espacenet |
| JP 2026004568 A | 2026-01-14 | 36227 | Q04771 | Espacenet |
| JP 2026004568 A | 2026-01-14 | 36231 | Q04771 | Espacenet |
| EP 4650780 A2 | 2025-11-19 | 2230 | Q04771 | Espacenet |
| JP 2025147176 A | 2025-10-06 | 194 | Q04771 | Espacenet |
| JP 2025147176 A | 2025-10-06 | 195 | Q04771 | Espacenet |
| JP 2025147176 A | 2025-10-06 | 196 | Q04771 | Espacenet |
1 to 10 of 173
See all 173 patentsDrugs6
Drugs a ChEMBL mechanism record says act on the gene's protein, through Open Targets.
| Drug | ChEMBL ID | Mechanism | Action | Source |
|---|---|---|---|---|
| DIBOTERMIN ALFA | CHEMBL2109171 | Activin receptor type-1 agonist | AGONIST | ChEMBL |
| EPTOTERMIN ALFA | CHEMBL2108594 | Activin receptor type-1 agonist | AGONIST | ChEMBL |
| MOMELOTINIB | CHEMBL1078178 | Activin receptor type-1 inhibitor | INHIBITOR | ChEMBL |
| MOMELOTINIB DIHYDROCHLORIDE MONOHYDRATE | CHEMBL6068336 | Activin receptor type-1 inhibitor | INHIBITOR | ChEMBL |
| PACRITINIB | CHEMBL2035187 | Activin receptor type-1 inhibitor | INHIBITOR | ChEMBL |
| PACRITINIB CITRATE | CHEMBL5095049 | Activin receptor type-1 inhibitor | INHIBITOR | ChEMBL |
Trials70
Trials of those drugs. A trial joins the gene only through a drug that acts on it.
| Trial | Drug | Phase | Results first posted | Source |
|---|---|---|---|---|
| NCT07569081 | MOMELOTINIB | PHASE2/PHASE3 | ClinicalTrials.gov | |
| NCT07498205 | MOMELOTINIB | PHASE4 | ClinicalTrials.gov | |
| NCT07447817 | PACRITINIB | PHASE2 | ClinicalTrials.gov | |
| NCT07424950 | MOMELOTINIB | PHASE2 | ClinicalTrials.gov | |
| NCT07394153 | PACRITINIB | PHASE2 | ClinicalTrials.gov | |
| NCT07387354 | PACRITINIB | PHASE1/PHASE2 | ClinicalTrials.gov | |
| NCT07226713 | PACRITINIB | PHASE2 | ClinicalTrials.gov | |
| NCT07148947 | PACRITINIB | PHASE2 | ClinicalTrials.gov | |
| NCT07104799 | MOMELOTINIB | PHASE1 | ClinicalTrials.gov | |
| NCT07098936 | MOMELOTINIB | PHASE2 | ClinicalTrials.gov |
1 to 10 of 70
See all 70 trialsNIH grants1,916
NIH grants whose papers are about the gene, through NIH's grant-paper links.
| Grant | Title | ACVR1 papers | Newest fiscal year |
|---|---|---|---|
| P30CA016672 | Cancer Center Support Grant | 15 | 2025 |
| P30CA008748 | Cancer Center Support Grant | 13 | 2025 |
| P01CA096832 | NORMAL & NEOPLASTIC GROWTH IN THE BRAIN | 11 | 2025 |
| P30AR069619 | Overall: Resource-based Center for Musculoskeletal Disorders Research (Overall Application) | 11 | 2025 |
| P30CA021765 | Cancer Center Support Grant (CCSG) | 10 | 2025 |
| P30CA060553 | The Robert H. Lurie Comprehensive Cancer Center | 7 | 2025 |
| P30CA068485 | Cancer Center Support Grant | 6 | 2025 |
| P50CA097257 | Brain Tumor SPORE Grant | 6 | 2025 |
| P30CA054174 | Mays Cancer Center at UT Health SA | 5 | 2025 |
| R01HL081397 | Mechanism of Matrix Gla Protein (MGP); Adipose Fibrosis | 5 | 2025 |
1 to 10 of 1,916Source NIH's project files
See all 1,916 nih grantsPapers2,859
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
| High-throughput spheroid profiling reveals BMP-driven rewiring of glioma cell death responses. | bioRxiv | 2026 | 42818713 | PubTator, text mining | PubMed |
| Reassessing the clinical value of momelotinib in myelofibrosis: An ESMO-MCBS:H-based appraisal of SIMPLIFY-1 and MOMENTUM. | Crit Rev Oncol Hematol | 2026 | 42800596 | PubTator, text mining | PubMed |
| Targeting TGFBR1 with the Investigational Inhibitor TP-6379 Improves Hematopoiesis in Low-Risk MDS Ex Vivo. | Cells | 2026 | 42782774 | PubTator, text mining | PubMed |
| PSMD14 as a translational target in cancer and beyond: from deubiquitination mechanisms to drug resistance and precision therapy. | Cancer Drug Resist | 2026 | 42729688 | PubTator, text mining | PubMed |
| Diffuse intrinsic pontine glioma in the era of H3 K27-altered diffuse midline glioma. | Crit Rev Oncol Hematol | 2026 | 42692100 | PubTator, text mining | PubMed |
| Immunogenomic profiling reveals targets for gene therapy in pediatric brain tumors. | Neurooncol Adv | 2026 | 42592420 | PubTator, text mining | PubMed |
| Hepcidin as a Molecular Hub of Iron Homeostasis: From BMP-SMAD Signaling to Therapeutic Modulation. | Biomolecules | 2026 | 42509741 | PubTator, text mining | PubMed |
| Fibrodysplasia Ossificans Progressiva: Clinicoradiological Insights Into a Rare Case. | Cureus | 2026 | 42504373 | PubTator, text mining | PubMed |
| Rare variant analysis of whole genome sequenced juvenile idiopathic arthritis multiplex pedigrees identifies rare variants in NOD2 and ACVR1. | G3 (Bethesda) | 2026 | 42466628 | PubTator, text mining | PubMed |
| A closed-loop cell therapy engineered to autonomously secrete activin A inhibitor protects from fibrodysplasia ossificans progressiva. | iScience | 2026 | 42433667 | PubTator, text mining | PubMed |
1 to 10 of 2,859
See all 2,859 papersSources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this gene from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/genes/v1/90
GET https://conductscience.org/api/genes/v1/90/patents?page=2